These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 19641184)

  • 21. Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming.
    Rodriguez-Ruiz ME; Rodriguez I; Garasa S; Barbes B; Solorzano JL; Perez-Gracia JL; Labiano S; Sanmamed MF; Azpilikueta A; Bolaños E; Sanchez-Paulete AR; Aznar MA; Rouzaut A; Schalper KA; Jure-Kunkel M; Melero I
    Cancer Res; 2016 Oct; 76(20):5994-6005. PubMed ID: 27550452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD137, an attractive candidate for the immunotherapy of lung cancer.
    Ye L; Jia K; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; He Y; Zhou C
    Cancer Sci; 2020 May; 111(5):1461-1467. PubMed ID: 32073704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function.
    Buchan SL; Dou L; Remer M; Booth SG; Dunn SN; Lai C; Semmrich M; Teige I; Mårtensson L; Penfold CA; Chan HTC; Willoughby JE; Mockridge CI; Dahal LN; Cleary KLS; James S; Rogel A; Kannisto P; Jernetz M; Williams EL; Healy E; Verbeek JS; Johnson PWM; Frendéus B; Cragg MS; Glennie MJ; Gray JC; Al-Shamkhani A; Beers SA
    Immunity; 2018 Nov; 49(5):958-970.e7. PubMed ID: 30446386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.
    Weigelin B; Bolaños E; Teijeira A; Martinez-Forero I; Labiano S; Azpilikueta A; Morales-Kastresana A; Quetglas JI; Wagena E; Sánchez-Paulete AR; Chen L; Friedl P; Melero I
    Proc Natl Acad Sci U S A; 2015 Jun; 112(24):7551-6. PubMed ID: 26034288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression.
    Hebb JPO; Mosley AR; Vences-Catalán F; Rajasekaran N; Rosén A; Ellmark P; Felsher DW
    Cancer Immunol Immunother; 2018 Jan; 67(1):47-60. PubMed ID: 28905118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity.
    Ho SK; Xu Z; Thakur A; Fox M; Tan SS; DiGiammarino E; Zhou L; Sho M; Cairns B; Zhao V; Xiong M; Samayoa J; Forsyth CM; Powers DB; Chao DT; Hollenbaugh D; Alvarez HM; Akamatsu Y
    Mol Cancer Ther; 2020 Apr; 19(4):1040-1051. PubMed ID: 31974274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity.
    Wilcox RA; Tamada K; Strome SE; Chen L
    J Immunol; 2002 Oct; 169(8):4230-6. PubMed ID: 12370353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intermittent chemotherapy can retain the therapeutic potential of anti-CD137 antibody during the late tumor-bearing state.
    Tongu M; Harashima N; Tamada K; Chen L; Harada M
    Cancer Sci; 2015 Jan; 106(1):9-17. PubMed ID: 25363339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD134 Costimulation Couples the CD137 Pathway to Induce Production of Supereffector CD8 T Cells That Become IL-7 Dependent.
    Lee SJ; Rossi RJ; Lee SK; Croft M; Kwon BS; Mittler RS; Vella AT
    J Immunol; 2007 Aug; 179(4):2203-14. PubMed ID: 17675480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 4-1BB agonism: adding the accelerator to cancer immunotherapy.
    Chester C; Ambulkar S; Kohrt HE
    Cancer Immunol Immunother; 2016 Oct; 65(10):1243-8. PubMed ID: 27034234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy.
    Imianowski CJ; Kuo P; Whiteside SK; von Linde T; Wesolowski AJ; Conti AG; Evans AC; Baird T; Morris BI; Fletcher NE; Yang J; Poon E; Lakins MA; Yamamoto M; Brewis N; Morrow M; Roychoudhuri R
    Cancer Res Commun; 2024 Aug; 4(8):2045-2057. PubMed ID: 38995700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
    van Ojik HH; Bevaart L; Dahle CE; Bakker A; Jansen MJ; van Vugt MJ; van de Winkel JG; Weiner GJ
    Cancer Res; 2003 Sep; 63(17):5595-600. PubMed ID: 14500400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD137 costimulation of CD8+ T cells confers resistance to suppression by virus-induced regulatory T cells.
    Robertson SJ; Messer RJ; Carmody AB; Mittler RS; Burlak C; Hasenkrug KJ
    J Immunol; 2008 Apr; 180(8):5267-74. PubMed ID: 18390707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].
    Alfaro C; Murillo O; Tirapu I; Azpilicueta A; Huarte E; Arina A; Arribillaga L; Pérez-Gracia JL; Bendandi M; Prieto J; Lasarte JJ; Melero I
    An Sist Sanit Navar; 2006; 29(1):77-96. PubMed ID: 16670731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human/mouse CD137 agonist, JNU-0921, effectively shrinks tumors through enhancing the cytotoxicity of CD8
    Liu L; Chen F; Li S; Yang T; Chen S; Zhou Y; Lin Z; Zeng G; Feng P; Shu HB; Zhou Q; Ding K; Chen L
    Sci Adv; 2024 Aug; 10(34):eadp8647. PubMed ID: 39178257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand.
    Kang SW; Lee SC; Park SH; Kim J; Kim HH; Lee HW; Seo SK; Kwon BS; Cho HR; Kwon B
    Cancer Res; 2017 Nov; 77(21):5989-6000. PubMed ID: 28923858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity.
    Eskiocak U; Guzman W; Wolf B; Cummings C; Milling L; Wu HJ; Ophir M; Lambden C; Bakhru P; Gilmore DC; Ottinger S; Liu L; McConaughy WK; He SQ; Wang C; Leung CL; Lajoie J; Carson WF; Zizlsperger N; Schmidt MM; Anderson AC; Bobrowicz P; Schuetz TJ; Tighe R
    JCI Insight; 2020 Mar; 5(5):. PubMed ID: 32161196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice.
    Niu L; Strahotin S; Hewes B; Zhang B; Zhang Y; Archer D; Spencer T; Dillehay D; Kwon B; Chen L; Vella AT; Mittler RS
    J Immunol; 2007 Apr; 178(7):4194-213. PubMed ID: 17371976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies.
    Lin W; Voskens CJ; Zhang X; Schindler DG; Wood A; Burch E; Wei Y; Chen L; Tian G; Tamada K; Wang LX; Schulze DH; Mann D; Strome SE
    Blood; 2008 Aug; 112(3):699-707. PubMed ID: 18519814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism.
    Eguren-Santamaría I; Rodríguez I; Herrero-Martin C; Fernández de Piérola E; Azpilikueta A; Sánchez-Gregorio S; Bolaños E; Gomis G; Molero-Glez P; Chacón E; Mínguez JÁ; Chiva S; Diez-Caballero F; de Andrea C; Teijeira Á; Sanmamed MF; Melero I
    Oncoimmunology; 2024; 13(1):2373519. PubMed ID: 38988823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.